Skip to content

Source filing unavailable

Q3 2017 · —
Revenue$17.50Mno prior Q3 2016 on file+13.9% vs Q2 2017
Net Income-$1.42Mno prior Q3 2016 on fileN/M vs Q2 2017
EPS Diluted-$3.14no prior Q3 2016 on fileN/M vs Q2 2017
Operating Income-$1,065,000—
Margins · derived
Operating margin-6.1%
Net margin-8.1%

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

no prior Q3 2016 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR